The Ludwig-Maximilians-University Munich (LMU) is the leading teaching and research university in Germany, ranking 1st in Germany in the latest Times Higher Education World University Ranking. With the neighboring Max-Planck, Helmholtz, and Technical University institutions, it can be regarded as a major European science hub. LMU is a large beneficiary of the German excellence initiative, and has hosted more than 40 ERC grants. In total, under the Seventh EU Framework Programme the LMU was recipient of 225 projects, in 22 of which it is/was the coordinating institution. In the first Health call in Horizon2020 the LMU received 7 grants.
The Institute for Stroke and Dementia Research (ISD) was launched in 2010 as a new clinical research institute integrating basic research, patient-oriented research, and patient care. It is part of the LMU Medical Center (Klinikum der Universität München, KUM), and financed by a private foundation.
LMU is the coordinator of SVDs@target and leads Work Package 6 (Project Management) and work package 5 on Interventions. Furthermore, LMU will contribute to all other work packages.As project coordinator LMU will seek for seamless translation between experimental and clinical studies and between individual work packages.
Prof. Martin Dichgans is the coordinator of SVDs@target.
He is a Professor of Neurology at the Ludwig-Maximilians-University Munich, endowed chair for Translational Stroke and Dementia Research; Director of the Institute for Stroke and Dementia Research (LMU KUM); Head of the interdisciplinary Stroke Center Munich (LMU); Executive committee member of the European Stroke Organisation (ESO); Board of directors of the German Stroke Society (DSG); major field of research: SVDs, stroke and dementia; specific expertise in: genetics, molecular biology, and imaging.
He has extensive experience in international and national collaborative projects and in the design and coordination of clinical trials. The group oversees one of the largest cohorts of patients with CADASIL (N>300) as well as sporadic SVDs (N>400), and one of the largest (N>3000) collections of biosamples from patients with ischemic stroke.
Prof. Dichgans is a work package leader (WP5, WP6) in SVDs@target.
Karin Waegemann, PhD is a research coordinator at the Institute for Stroke and Dementia Research. She has a background in Biology and ample experience in the management of international projects and clinical trials. She supported the application process and the contract negotations for the project and takes care of all project management issues related to SVDs@target in close contact with ARTTIC.
Anna Kopczak, MD is a neurologist and clinician scientist at the Institute for Stroke and Dementia Research. She is a lecturer at the Ludwig-Maximilians-University Munich. Her major research interests are the interface between Neurology and Internal Medicine. Her focus is on interdisciplinary approaches of understanding brain injuries such as stroke. She joined the Institute for Stroke and Dementia Research in 2016 to coordinate the clinical trials in SVDs@target.